CRESCENT BIOPHARMA, INC. (CBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 7M 14M 21M Q4 '13: 4M Q1 '14: 185.1K Q2 '14: 15.2M Q3 '14: 15.1M Q4 '14: 15M Q1 '15: 15M Q2 '15: 20M Q3 '15: 20M Q4 '15: 20.1M Q4 '20: 10.2M Q1 '21: 2.2M Q2 '21: 2.2M Q3 '21: 1.3M Q4 '21: 1.2M Q1 '22: 104.3K Q2 '22: 179.2K Q3 '22: 92.6K Q4 '22: 75K Q2 '14 Q1 '15 Q4 '15 Q2 '21 Q1 '22 Q4 '22

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '13: -10.6M Q1 '14: -16.2M Q2 '14: -4.6M Q3 '14: -7.6M Q4 '14: -11.1M Q1 '15: -13.1M Q2 '15: -10.8M Q3 '15: -11.3M Q4 '15: -12.8M Q1 '16: -13.2M Q2 '16: -31.7M Q3 '16: -32.4M Q4 '16: -31.9M Q1 '17: -32.3M Q2 '17: -32.5M Q3 '17: -32.8M Q4 '17: -33.9M Q1 '18: -38.1M Q2 '18: -42M Q3 '18: -46.4M Q4 '18: -51.8M Q1 '19: -54.8M Q2 '19: -59.4M Q3 '19: -61M Q4 '19: -61.4M Q1 '20: -54.4M Q2 '20: -51.7M Q3 '20: -51.3M Q4 '20: -51.5M Q1 '21: -57.7M Q2 '21: -58M Q3 '21: -61.6M Q4 '21: -63.4M Q1 '22: -63.8M Q2 '22: -62.8M Q3 '22: -54.2M Q4 '22: -47.4M Q1 '23: -43.7M Q2 '23: -39.3M Q3 '23: -40.3M Q4 '23: -39.3M Q1 '24: -39.4M Q2 '24: -40.9M Q3 '24: -42.3M Q4 '24: -47.3M Q1 '25: -50.4M Q2 '25: -61M Q3 '25: -75.7M Q4 '25: -152.6M Q1 '26: -163.1M Q2 '26: -168.5M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-105M -70M -35M 0 35M 70M 105M Q4 '13: -10.6M Q1 '14: -16.2M Q2 '14: -4.7M Q3 '14: -7.6M Q4 '14: -11.1M Q1 '15: -13.1M Q2 '15: -10.7M Q3 '15: -11.3M Q4 '15: -12.8M Q1 '16: -13.2M Q2 '16: -31.7M Q3 '16: -32.4M Q4 '16: -31.8M Q1 '17: -32.2M Q2 '17: -32.3M Q3 '17: -32.4M Q4 '17: -33.3M Q1 '18: -36.6M Q2 '18: -39.8M Q3 '18: -43.4M Q4 '18: -48M Q1 '19: -50.8M Q2 '19: -55.4M Q3 '19: -57.1M Q4 '19: -57.9M Q1 '20: -51.5M Q2 '20: -49.7M Q3 '20: -50.2M Q4 '20: -51M Q1 '21: -57.6M Q2 '21: -58M Q3 '21: -61.6M Q4 '21: -63.4M Q1 '22: -63.8M Q2 '22: -62.7M Q3 '22: -53.9M Q4 '22: -46.7M Q1 '23: -42.4M Q2 '23: -37.4M Q3 '23: -38.1M Q4 '23: -36.9M Q1 '24: -37.3M Q2 '24: -39.1M Q3 '24: -39.7M Q4 '24: -45.9M Q1 '25: -50.3M Q2 '25: -62M Q3 '25: -76.8M Q4 '25: -84.8M Q1 '26: -93M Q2 '26: -96M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '13: -15.5M Q1 '14: -14.2M Q2 '14: -2.3M Q3 '14: -3.7M Q4 '14: -4.3M Q1 '15: -10.4M Q2 '15: -25.8M Q3 '15: -7.4M Q4 '15: -8.2M Q1 '16: -8.8M Q2 '16: -9.7M Q3 '16: -30.7M Q4 '16: -29.7M Q1 '17: -29.6M Q2 '17: -28.6M Q3 '17: -27.4M Q4 '17: -29.8M Q1 '18: -30.9M Q2 '18: -37.9M Q3 '18: -41.7M Q4 '18: -43.3M Q1 '19: -47.5M Q2 '19: -45.8M Q3 '19: -49.2M Q4 '19: -52M Q1 '20: -41.1M Q2 '20: -44.3M Q3 '20: -42.3M Q4 '20: -39.2M Q1 '21: -49.9M Q2 '21: -48.9M Q3 '21: -54.4M Q4 '21: -57.5M Q1 '22: -57.1M Q2 '22: -59.7M Q3 '22: -51.4M Q4 '22: -46.5M Q1 '23: -44.4M Q2 '23: -35.1M Q3 '23: -35.2M Q4 '23: -34.9M Q1 '24: -33.8M Q2 '24: -35.7M Q3 '24: -35M Q4 '24: -33.7M Q1 '25: -34M Q2 '25: -41.5M Q3 '25: -51.1M Q4 '25: -71.5M Q1 '26: -69.6M Q2 '26: -72.7M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q4 '13: -15.6M Q1 '14: -14.3M Q2 '14: -2.5M Q3 '14: -3.9M Q4 '14: -4.5M Q1 '15: -10.6M Q2 '15: -26.1M Q3 '15: -7.7M Q4 '15: -8.5M Q1 '16: -9.1M Q2 '16: -9.8M Q3 '16: -31M Q4 '16: -30.4M Q1 '17: -30.3M Q2 '17: -29.5M Q3 '17: -28.1M Q4 '17: -30.1M Q1 '18: -31.2M Q2 '18: -38M Q3 '18: -41.8M Q4 '18: -43.5M Q1 '19: -47.6M Q2 '19: -46M Q3 '19: -49.4M Q4 '19: -52.1M Q1 '20: -41.3M Q2 '20: -44.3M Q3 '20: -42.4M Q4 '20: -39.3M Q1 '21: -49.9M Q2 '21: -49M Q3 '21: -54.4M Q4 '21: -57.5M Q1 '22: -57.1M Q2 '22: -59.8M Q3 '22: -51.4M Q4 '22: -46.5M Q1 '23: -44.4M Q2 '23: -35.1M Q3 '23: -35.2M Q4 '23: -34.9M Q1 '24: -33.8M Q2 '24: -35.7M Q3 '24: -35M Q4 '24: -33.7M Q1 '25: -34M Q2 '25: -41.7M Q3 '25: -51.8M Q4 '25: -72.5M Q1 '26: -70.7M Q2 '26: -73.6M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '13: 11.1M Q2 '13: 946.4K Q1 '14: 17.2M Q2 '14: 20.2M Q3 '14: 18.9M Q2 '15: 20.2M Q3 '15: 19M Q2 '16: 19.8M Q1 '21: 50.7M Q2 '21: 51.5M Q3 '21: 51.6M Q1 '22: 52.3M Q2 '22: 52.4M Q3 '22: 52.4M Q1 '23: 64.5M Q2 '23: 64.3M Q3 '23: 64.3M Q1 '24: 64.5M Q2 '24: 64.5M Q3 '24: 64.5M Q1 '25: 64.5M Q1 '14 Q2 '15 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '13: -9.46 Q1 '14: -9.80 Q2 '14: -5.71 Q3 '14: -3.06 Q4 '14: -0.65 Q1 '15: -0.72 Q2 '15: -0.60 Q3 '15: -0.63 Q4 '15: -0.71 Q1 '16: -0.74 Q2 '16: -1.66 Q3 '16: -1.62 Q4 '16: -1.51 Q1 '17: -1.45 Q2 '17: -1.34 Q3 '17: -1.24 Q4 '17: -1.15 Q1 '18: -1.07 Q2 '18: -1.03 Q3 '18: -1.06 Q4 '18: -1.11 Q1 '19: -1.18 Q2 '19: -1.29 Q3 '19: -1.33 Q4 '19: -1.35 Q1 '20: -1.20 Q2 '20: -1.15 Q3 '20: -1.13 Q4 '20: -1.12 Q1 '21: -1.22 Q2 '21: -1.18 Q3 '21: -1.23 Q4 '21: -1.23 Q1 '22: -1.23 Q2 '22: -1.20 Q3 '22: -1.02 Q4 '22: -0.88 Q1 '23: -0.77 Q2 '23: -0.65 Q3 '23: -0.63 Q4 '23: -0.58 Q4 '14 Q2 '16 Q4 '17 Q2 '19 Q4 '20 Q2 '22 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.